左旋多巴使用与帕金森病患者冻结步态特征:NS-Park与PPMI队列研究
该研究基于NS-Park和PPMI两个前瞻性多中心队列,纳入25,602例和1,441例帕金森病患者,采用混合效应有序逻辑回归及生存分析评估左旋多巴使用与冻结步态(FOG)严重程度及新发的关系。校正疾病病程和严重程度后,左旋多巴与FOG严重程度或新发均无显著一致关联,而疾病病程、H&Y分期和MDS-UPDRS III评分与FOG严重程度独立相关。
要点
- 校正病程和严重程度后,左旋多巴与FOG严重程度无显著关联。
- 左旋多巴暴露未显著增加新发FOG风险。
- 疾病病程、H&Y分期和MDS-UPDRS III评分是FOG严重程度的主要驱动因素。
核心结论
- 校正疾病病程和严重程度后,左旋多巴暴露与FOG严重程度或新发风险无显著或一致关联,效应估计值明显衰减但仍有不确定性。
研究设计与样本
- 研究纳入NS-Park队列25,602例和PPMI队列1,441例帕金森病患者,均至少完成2次访视。
- 根据疾病病程、基线FOG和左旋多巴暴露定义三个嵌套亚队列。
- FOG采用MDS-UPDRS Part II 2.13评估,分析采用混合效应有序逻辑回归、Kaplan-Meier和Cox比例风险模型。
主要发现
- 未校正分析中,NS-Park队列左旋多巴使用与更高的FOG严重程度和发生率相关,但PPMI队列中该关联无统计学意义。
- 混合效应有序逻辑回归校正后,左旋多巴状态对FOG的效应不显著(NS-Park OR 1.84,95%CI 0.94-3.61,p=0.074;PPMI OR 0.76,95%CI 0.38-1.51,p=0.430)。
- 疾病病程(NS-Park OR 4.4,95%CI 3.01-6.29,p=6.0e-15;PPMI OR 6.97,95%CI 5.05-9.63,p=4.7e-32)、H&Y分期(NS-Park OR 6.8,95%CI 3.52-13.08,p=1.059e-08;PPMI OR 1.5,95%CI 0.96-2.22,p=0.073)和MDS-UPDRS-III评分(NS-Park OR 1.85,95%CI 1.38-2.49,p=4.34e-05;PPMI OR 2.00,95%CI 1.67-2.39,p=2.4e-14)与FOG严重程度独立相关。
- 未来左旋多巴暴露与新发FOG无统计学显著关联。
- 新发FOG由H&Y分期(NS-Park HR 1.94,95%CI 1.68-2.23;PPMI HR 1.78,95%CI 1.47-2.17)和MDS-UPDRS III评分(NS-Park HR 1.40,95%CI 1.07-1.83;PPMI HR 1.26,95%CI 1.17-1.36)驱动。
关键数值与推荐
- FOG评估采用MDS-UPDRS Part II 2.13。
- 左旋多巴与FOG严重程度关联的校正OR:NS-Park 1.84(95%CI 0.94-3.61,p=0.074),PPMI 0.76(95%CI 0.38-1.51,p=0.430)。
- 疾病病程与FOG严重程度关联的OR:NS-Park 4.4(95%CI 3.01-6.29,p=6.0e-15),PPMI 6.97(95%CI 5.05-9.63,p=4.7e-32)。
- H&Y分期与新发FOG关联的HR:NS-Park 1.94(95%CI 1.68-2.23),PPMI 1.78(95%CI 1.47-2.17)。
临床怎么用
- 临床评估帕金森病FOG风险时,应重点关注疾病病程、H&Y分期和运动症状严重程度,而非左旋多巴使用本身。
- 对于已使用左旋多巴的患者,FOG的出现或加重更可能反映疾病进展,需综合评估而非简单归因于药物。
局限性
- 残留混杂和不确定性仍存在,效应估计值衰减但未完全排除关联可能。
- 研究为观察性设计,无法确立因果关系。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Recent reports have suggested that levodopa exposure may contribute to freezing of gait (FOG), but this relationship remains controversial because of confounding by disease severity and duration. Our goal was to assess the relationship between levodopa use and FOG incidence and severity. METHODS: We studied 2 prospective, multicentric cohorts: NS-Park and Parkinson's Progression Markers Initiative (PPMI). Patients with ≥2 visits were selected. Three nested subcohorts were defined based on disease duration, baseline FOG, and levodopa exposure. FOG was assessed using the Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part II 2.13. Analyses included mixed-effects ordered logistic regression to evaluate FOG severity and Kaplan-Meier and Cox proportional hazards models to assess incident FOG. Models adjusted for disease duration, Hoehn and Yahr (H&Y) stage, and MDS-UPDRS Part III scores. RESULTS: A total of 25,602 patients with Parkinson disease from the NS-Park (mean age 68.3 ± 29.1, 42% female) and 1,441 from the PPMI (mean age 62.9 ± 9.8, 37% female) cohorts were included. In unadjusted analyses with the NS-Park cohort, levodopa use was associated with higher FOG severity and incidence, but this association was no longer statistically significant in the PPMI cohort. In mixed-effects ordinal logistic regression models adjusting for disease duration/severity, levodopa status showed a nonsignificant effect size on FOG (NS-Park odds ratio [OR] 1.84, 95% CI 0.94-3.61, p = 0.074; PPMI OR 0.76, 95% CI 0.38-1.51, p = 0.430), while disease duration (NS-Park OR 4.4, 95% CI 3.01-6.29, p = 6.0e-15; PPMI OR 6.97, 95% CI 5.05-9.63, p = 4.7e-32), Hoehn & Yahr stage (NS-Park OR 6.8, 95% CI 3.52-13.08, p = 1.059e-08; PPMI OR 1.5, 95% CI 0.96-2.22, p = 0.073), and MDS-UPDRS-III score (NS-Park OR 1.85, 95% CI 1.38-2.49, p = 4.34e-05; PPMI OR 2.00, 95% CI 1.67-2.39, p = 2.4e-14) were independently associated with greater FOG severity. No statistically significant association was observed between future levodopa exposure and de novo FOG incidence. In turn, FOG incidence was driven by the H&Y (NS-Park: hazard ratio [HR] 1.94, 95% CI 1.68-2.23; PPMI: HR 1.78, 95% CI 1.47-2.17) and MDS-UPDRS III (NS-Park: HR 1.40, 95% CI 1.07-1.83; PPMI: HR 1.26, 95% CI 1.17-1.36). DISCUSSION: No significant or consistent association between levodopa exposure and FOG severity or incidence was observed after adjustment for disease duration and severity, with the effect estimates significantly attenuated despite residual uncertainty.
引用
- Barbosa R, Bastos P, Rascol O, et al. Levodopa Use and Characteristics of Freezing-of-Gait in Patients With Parkinson Disease in the NS-Park and PPMI Cohorts. Neurology. 2026. PMID: 42715510. doi:10.1212/WNL.0000000000218515
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。